Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
January 2025 — Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Dimainvest is a holding company owned by Umberto Di Maio, the controlling shareholder of Shedir Pharma Group.
Shedir Pharma Group manufactures and distributes nutraceuticals, cosmetics and medical devices. The company is headquartered in Piano di Sorrento, Italy.
Our role in the transaction
Oaklins Italy’s parent company, Banca Akros, acted as the appointed broker for the collection of shares in the voluntary public tender offer for 11.9% of Shedir Pharma Group’s shares by Dimainvest.
Contacter l'équipe de la transaction
Transactions connexes
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
En apprendre plusVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
En apprendre plusKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
En apprendre plus